 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2021 and provided business updates. The momentum we are seeing with STK-001 in the clinic is driven by high levels of interest from the Dravet community and our shared sense of urgency to advance a potential disease- 